This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article provides insufficient context for those unfamiliar with the subject. Please help improve the article by providing more context for the reader. (April 2014) (Learn how and when to remove this template message) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Otilonium bromide" – news · newspapers · books · scholar · JSTOR (January 2018) (Learn how and when to remove this template message) (Learn how and when to remove this template message)
Otilonium bromide
Clinical data
Trade namesSpasmoctyl 40, Doralin
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • N,N-Diethyl-N-methyl-2-(4-[2-(octyloxy)benzamido]benzoyloxy)ethanaminium bromide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.043.128 Edit this at Wikidata
Chemical and physical data
FormulaC29H43BrN2O4
Molar mass563.577 g·mol−1
3D model (JSmol)
  • CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC.[Br-]
  • InChI=1S/C29H42N2O4.BrH/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3;/h12-13,15-20H,5-11,14,21-23H2,1-4H3;1H ☒N
  • Key:VWZPIJGXYWHBOW-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Otilonium bromide, sold under the trade name Spasmomen among others, is an antimuscarinic and calcium channel blocker used to relieve spasmodic pain of the gut, especially in irritable bowel syndrome.[1]

Medical uses

A pooled analysis of three clinical trials suggest that otilonium is more effective than placebo for the treatment of irritable bowel syndrome.[2]

Pharmacology

Otilinium binds to both muscarinic receptors and tachykinin NK2 receptors.[3] It has been shown to inhibit L-type and T-type calcium channels, actions which may contribute to or determine its effects in the gut.[4][5]

When taken orally, very little of the drug is absorbed into the rest of the body,[6] which means that most of its actions remain confined to the gastrointestinal system.

References

  1. ^ "Dismox" (PDF). Archived from the original (PDF) on 4 March 2016.
  2. ^ Clavé P, Tack J (March 2017). "Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis". Therapeutic Advances in Gastroenterology. 10 (3): 311–322. doi:10.1177/1756283X16681708. PMC 5305018. PMID 28246548.
  3. ^ Evangelista S (1999). "Otilonium bromide: a selective spasmolytic for the gastrointestinal tract". The Journal of International Medical Research. 27 (5): 207–22. doi:10.1177/030006059902700501. PMID 10689627.
  4. ^ Martin MT, Hove-Madsen L, Jimenez M (April 2004). "Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon". Neurogastroenterology and Motility. 16 (2): 175–83. doi:10.1111/j.1365-2982.2004.00518.x. PMID 15086871.
  5. ^ Strege PR, Sha L, Beyder A, Bernard CE, Perez-Reyes E, Evangelista S, et al. (May 2010). "T-type Ca(2+) channel modulation by otilonium bromide". American Journal of Physiology. Gastrointestinal and Liver Physiology. 298 (5): G706-13. doi:10.1152/ajpgi.00437.2009. PMC 2867415. PMID 20203058.
  6. ^ Shin BS, Kim JJ, Kim J, Hu SK, Kim HJ, Hong SH, et al. (January 2008). "Oral bioavailability and enterohepatic recirculation of otilonium bromide in rats". Archives of Pharmacal Research. 31 (1): 117–24. doi:10.1007/s12272-008-1129-2. PMID 18277617. S2CID 25727036.